Inside the Testa Bioprocess Innovation Center

By Flora Southey contact

- Last updated on GMT

Related tags: Ge healthcare, Sweden

Biopharma-Reporter takes you inside the recently opened Testa BioProcess Innovation Center in Uppsala, Sweden, and speaks with CEO of GE Nordics, Lotta Ljungqvist.

The Testa Center opened in August, 2018 to help academics, startups and biopharmaceutical companies develop and scale-up production. The centre is owned and operated by GE Healthcare Life Sciences as a non-profit company, but received SEK 100m in funding from the Swedish government.

At the time of launch, Sweden’s minister for entreprise and innovation, Mikael Damberg, described the centre as an impressive test bed​”. ​The Testa Center “promotes innovation, strengthens competitiveness, and will help us provide more efficient care in the future,” ​he added.

According to CEO of GE Nordics and the Testa Center, Lotta Ljungqvist​, the centre will benefit startups and SMEs by offering a “lower cost of accessing the facility and also reduced risk”.

The project is designed to support innovation in the life science community, she told us. “The ones driving innovation and new needs are really the entrepreneurs and startups…the Testa Center is a good way for us to interact with that scene,” ​she added.

Watch the video to look inside the 2,500m² centre and its four bioprocessing laboratories. 

Related news

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers